Genus PLC operates under a business model focused on animal genetics. As a leading global provider of innovative genetic solutions, Genus specializes in enhancing the productivity and sustainability of livestock farming. The company offers a wide range of products and services, including bovine and porcine genetic evaluation and improvement, as well as reproductive technologies. By leveraging cutting-edge genetic technologies, Genus aims to help livestock producers achieve improved profitability, efficiency, and sustainability. With a strong commitment to research and development, Genus continues to drive advancements in animal genetics, contributing to the overall growth and success of the industry.

Genus PLC is primarily active in the animal genetics industry. With a solid reputation and global presence, the company specializes in animal breeding and genetics, facilitating improvements in livestock productivity and efficiency. Genus PLC's innovative solutions are widely utilized in various sectors, including cattle, pigs, and aquaculture. Leveraging cutting-edge biotechnology and extensive research, the company enables farmers and producers to enhance their animals' genetic potential, resulting in higher-quality products and increased profitability. Genus PLC's commitment to genetic advancement and technological expertise solidify its position as a leading player in the animal genetics industry.

The main competitors of Genus PLC in the market include companies such as Neogen Corporation, Zoetis Inc., and Hendrix Genetics.

Genus PLC is a renowned company with a rich history and impressive background. Established in 1935, it has evolved into a global leader in animal genetic improvement. With a primary focus on breeding and biotechnology, Genus PLC constantly strives to enhance livestock productivity and quality through innovative genetic solutions. The company has a strong track record of delivering cutting-edge technologies and services, catering to the agricultural and food production sectors worldwide. Genus PLC's commitment to research and development, along with its unrivaled expertise, has solidified its position as a trusted partner for farmers and producers, revolutionizing the livestock industry.

Genus PLC has achieved several significant milestones, solidifying its position as a leading biotechnology company. One of the notable accomplishments includes the successful launch of their proprietary genetic improvement technologies, which have revolutionized the livestock industry. Additionally, the company has expanded its global presence by establishing strategic partnerships and collaborations, enabling the development and delivery of innovative solutions to animal breeding challenges. Through continuous research and development efforts, Genus PLC has introduced groundbreaking genetic traits that enhance productivity, animal health, and welfare. Moreover, their commitment to sustainable development and responsible practices has earned them recognition in the industry. Genus PLC continues to drive advancements in animal genetics, contributing to the growth and success of the agricultural sector.

Genus PLC is primarily present in various countries and regions worldwide. The company has a global presence, with key operations and business activities spanning across different continents. Genus PLC operates in North America, including the United States and Canada, where it has established significant market presence. Additionally, the company maintains a strong presence in Europe, with operations in countries such as the United Kingdom, Germany, France, and the Netherlands. Genus PLC also operates in key regions of Latin America, Asia-Pacific, and Africa, expanding its reach and serving customers in diverse markets around the globe.

Genus PLC represents a values-driven corporate philosophy focused on innovation, sustainability, and delivering value to stakeholders. The company prioritizes genetic improvement in animal breeding, aiming to enhance productivity and profitability for its customers. Genus PLC upholds high standards of animal welfare, ensuring healthy and sustainable food production. With a commitment to research and development, the company continually strives for advancements in its industry. Genus PLC emphasizes collaboration, integrity, and responsibility throughout its operations, fostering strong partnerships and maintaining a global presence. Through its dedication to excellence and ethical practices, Genus PLC consistently demonstrates its commitment to enhancing livestock genetics and driving positive change in the agricultural sector.

Analysts currently set an average price target of 3,164.38 GBP for the Genus stock (median: 3,264.00 GBP), implying +14,714.5 % versus the latest price. The consensus is based on 17 analyst ratings.

Genus Analyst Price Targets 2026

17 analysts currently rate the Genus stock: 15 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Genus to generate revenue of 729.31 M GBP and earnings per share of 1.00 GBP.

Genus Analyst Price Targets 2026

Converted at the current exchange rate, the Genus share trades at 0.25 EUR (0.21 GBP).

The Genus share (GNS.L) is listed on 4 stock exchanges, including: Frankfurt (GBE.F), London (GNS.L), London (GNS.L).

Genus PLC is a global leader in innovative animal breeding and genomics products. It operates in three core divisions: genetics, health, and agriculture. With a global network of customers, partners, and branches in over 70 countries, the company aims to utilize animal genetics for sustainable and profitable agriculture. The genetics division of Genus develops and supplies animal genetics for pigs and cattle to customers worldwide. The company utilizes advanced technologies and methods to develop innovative products that enhance growth characteristics, meat quality, feed efficiency, and milk production. Examples of products in the genetics division include the "PIC" pig genetics and the "ABS" cattle genetics, which have a strong market presence globally. The health division of Genus offers veterinary products and services for animal health. The company provides a wide range of vaccines, therapeutics, and medical services for livestock. One well-known product in this division is "PigSAFE," which is a program for improving biosecurity in pig farms. With the support of health services, animal health is protected and improved, resulting in better yields for breeders and farmers. The agriculture division of Genus aims to contribute to the sustainability, efficiency, and effectiveness of agriculture through innovative agricultural practices and technologies. The company supports customers worldwide in improving the productivity and profitability of farms. They utilize data and analysis to enable better decision-making and improve the efficiency of the value chain. Examples of products and services in this division include "Sexcel," an in-vitro fertilization services company, and "Strawman," an online auction platform for cattle semen. In summary, Genus PLC aims to offer innovative products and services for breeders and farmers to improve the efficiency, profitability, and sustainability of agriculture. With three core divisions - genetics, health, and agriculture - the company has a broad portfolio of products and services to support customers worldwide. The use of advanced technologies and methods helps secure the company's competitive advantage and make it a significant player in the agriculture and animal genomics industry. The answer is: Genus PLC is a global leader in innovative animal breeding and genomics products.

The expected revenue of Genus is 729.31 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genus is 66.89 M GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genus is currently 0.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genus stock.

The price-to-sales ratio (P/S) of Genus is currently 0.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genus stock.

The Eulerpool Quality Score for Genus is 7/10.

The ISIN of Genus is GB0002074580. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genus is 762548. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genus is GNS.L. The ticker symbol is used to trade Genus shares on the stock exchange.

Over the past 12 months, Genus paid a dividend of 0.32 GBP . This corresponds to a dividend yield of about 149.81 %. For the coming 12 months, Genus is expected to pay a dividend of 0.45 GBP.

The current dividend yield of Genus is 149.81 %.

Genus pays a dividend, distributed in the months of , , , .

Genus paid dividends every year for the past 25 years.

For the upcoming 12 months, dividends amounting to 0.45 GBP are expected. This corresponds to a dividend yield of 208.39 %.

Genus is assigned to the 'Health' sector.

To receive the latest dividend of Genus from amounting to 0.22 GBP, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Genus distributed 0.32 GBP as dividends.

The dividends of Genus are distributed in GBP.